Cytokinetics, Inc. (CYTK) Tops Q3 EPS by 5c; Guides FY11 Revs Below
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $78.78 +0.86%
EPS Growth %: -46.4%
Financial Fact:
Income tax benefit: 0
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -46.4%
Financial Fact:
Income tax benefit: 0
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q3 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.36 million.
Sees FY2011 revenue of $3.0-$4.0 million, versus the consensus of $5.62 million.
Sees FY2011 revenue of $3.0-$4.0 million, versus the consensus of $5.62 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- RBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move'
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
